title: Alcohol-induced organic cerebral psychosyndromes: partial reversal of cognitive impairments assisted by dihydroergocristine.
abstract: Chronic alcohol abusers show a specific pattern of cerebral damage associated with cognitive and behavioral defects known as the organic cerebral psychosyndrome, which is partially reversible upon discontinuation of ethanol consumption. To assess the potential of nootropic drug therapy in alcohol rehabilitation in a double-blind study design, 56 consecutive patients who participated in routine rehabilitation therapy received 2 x 3 mg/day dihydroergocristine or placebo in tablet form over 6-13 weeks. Forty-nine patients completed the protocol. Although significant improvement was seen in both groups, we could document a specific cognitive restitution effect attributable to dihydroergocristine. Significant differences in favor of the active drug group were demonstrated by Mini-Mental State Examination, Syndrome Brief Test, Paired Words Test, in the neuropsychiatric Brief Cognitive Rating Scale assessments, and in the Clinical Global Impression of Change rating. No significant between-group differences were found in the Digit Symbol Test and the Block Design Test as well as in the Brief Psychiatric Rating Scale (BPRS). Dihydroergocristine was equivalent to placebo in terms of subjective drug tolerance, lack of side effects, and laboratory parameters. Based on this profile of efficacy and safety, we recommend dihydroergocristine as an adjuvant drug in alcohol rehabilitation.
authors.affiliation: Donauspital, Sozialmedizinisches Zentrum Ost, Wien, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Rainer
authors.forename: H A
authors.initials: HA
authors.lastname: Mucke
authors.forename: K
authors.initials: K
authors.lastname: Chwatal
authors.forename: L
authors.initials: L
authors.lastname: Havelec
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000150:complications* / Q000534:rehabilitation; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000627:therapeutic use*; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D018697:Nootropic Agents; D004088:Dihydroergotoxine